

If the following information is not complete, correct, or legible, the SA process can be delayed.

Please use one form per member.

Preferred drugs Droxia® Endari®, Xromi (if <2 year of age) and Siklos® (if age 2–17) do not require a SA.

**MEMBER INFORMATION**

Last Name:

First Name:

Medicaid ID Number:

Date of Birth:

Weight in Kilograms: \_\_\_\_\_

**PRESCRIBER INFORMATION**

Last Name:

First Name:

NPI Number:

Phone Number:

Fax Number:

**DRUG INFORMATION**

Drug Name/Form:  Adakveo®  Siklos® (if 18 years of age or older)  glutamine powder packet   
Xromi (if 2 years of age or older)

Strength: \_\_\_\_\_

Dosing Frequency: \_\_\_\_\_

Length of Therapy: \_\_\_\_\_

Quantity per Day: \_\_\_\_\_

*(Form continued on next page.)*

Member's Last Name:

Member's First Name:

---

**DIAGNOSIS AND MEDICAL INFORMATION**

---

**For initial approval, complete the following questions to receive a 6-month approval:**

1. Is the drug being prescribed by or in consultation with an oncologist, hematologist, or sickle cell specialist?  
 Yes       No
2. Does the member have a diagnosis of sickle cell disease presenting as one of following: HbSS, HbSC, HbS $\beta^0$ -thalassemia, or HbS $\beta^+$ -thalassemia? **AND**  
 Yes       No
3. Is the medication/dose proper for the member's age or other conditions affecting the dose, according to the FDA-approved product package insert?  
 Yes       No

**For Adakveo®:**

4. Has the member had an insufficient response to a minimum 3-month trial of hydroxyurea (unless contraindicated or intolerant)? **AND**  
 Yes       No
5. Has the member experienced **TWO** or more vaso-occlusive crises (VOC) in the previous year, despite hydroxyurea therapy?  
 Yes       No

**For Siklos® (hydroxyurea):**

6. Is the member 18 years of age or older?  
 Yes       No
  7. Is the brand Siklos® medically necessary? If yes, please provide explanation below.  
 Yes       No
- 

**For Xromi (hydroxyurea solution):**

8. Is the member 2 years of age or older?  
 Yes       No
  9. Is the Xromi solution medically necessary? If yes, please provide explanation below.  
 Yes       No
- 

*(Form continued on next page.)*

**Member's Last Name:** \_\_\_\_\_ **Member's First Name:** \_\_\_\_\_

**For generic glutamine powder packet:**

10. Has the member had an insufficient response to a minimum 3-month trial of brand name Endari®?

Yes  No

**For renewal, complete the following questions to receive a 12-month approval:**

1. Does the member continue to meet the above criteria? **AND**

Yes  No

2. Does the member have disease response improvement with treatment?

Yes  No

**For Adakveo®:**

3. Is the member's response compared to pre-treatment baseline evidenced by a decrease in the frequency of vaso-occlusive crises (VOC) necessitating treatment, reduction in number or duration of hospitalizations, and/or reduction in severity of VOC?

Yes  No

\_\_\_\_\_  
**Prescriber Signature (Required)**

\_\_\_\_\_  
**Date**

By signature, the physician confirms the above information is accurate and verifiable by member records.

Please include ALL requested information; incomplete forms will delay the SA process.

Submission of documentation does NOT guarantee coverage by the Department of Medical Assistance Services.

Fax this form to 1-866-940-7328

Pharmacy PA Call Center 1-800-310-6826

Confidentiality Notice: The documents accompanying this transmission contain confidential health information that is legally privileged. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or action taken in reliance on the contents of these documents is strictly prohibited. If you have received this information in error, please notify the sender (via return fax) immediately and arrange for the return or destruction of these documents. Distribution, reproduction or any other use of this transmission by any party other than the intended recipient is strictly prohibited.